Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

BACKGROUND: In the BOLERO-2 trial, everolimus (EVE), an inhibitor of mammalian target of rapamycin, demonstrated significant clinical benefit with an acceptable safety profile when administered with exemestane (EXE) in postmenopausal women with hormone receptor-positive (HR(+)) advanced breast cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Rugo, H. S., Pritchard, K. I., Gnant, M., Noguchi, S., Piccart, M., Hortobagyi, G., Baselga, J., Perez, A., Geberth, M., Csoszi, T., Chouinard, E., Srimuninnimit, V., Puttawibul, P., Eakle, J., Feng, W., Bauly, H., El-Hashimy, M., Taran, T., Burris, H. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969554/
https://www.ncbi.nlm.nih.gov/pubmed/24615500
http://dx.doi.org/10.1093/annonc/mdu009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969554/
https://www.ncbi.nlm.nih.gov/pubmed/24615500
http://dx.doi.org/10.1093/annonc/mdu009

Ejemplares similares